Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live ... CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. Show more
Ask ADVFN Intelligence (AI)
IRVINE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting...
– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 – – Encouraging data adds to the body of evidence...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.3 | 3.98773006135 | 32.6 | 35.22 | 31.28 | 529172 | 33.01046409 | CS |
| 4 | -2.365 | -6.52143940438 | 36.265 | 40.47 | 31.28 | 463254 | 35.27502197 | CS |
| 12 | -1.41 | -3.99320305862 | 35.31 | 40.47 | 31.28 | 658456 | 36.89828661 | CS |
| 26 | 0.91 | 2.75841163989 | 32.99 | 40.47 | 29.26 | 615332 | 35.38187472 | CS |
| 52 | 4.9 | 16.8965517241 | 29 | 50.23 | 25.77 | 653907 | 36.18117717 | CS |
| 156 | 4.9 | 16.8965517241 | 29 | 50.23 | 25.77 | 653907 | 36.18117717 | CS |
| 260 | 4.9 | 16.8965517241 | 29 | 50.23 | 25.77 | 653907 | 36.18117717 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
